(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Building a Maintainable Closet: Individual Excursions in Moral Style - 26 Nations for Setting up camp
- 3A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- 4Vote in favor of Your #1 sort of pie
- 5How does spider venom damage human cells? Researchers uncover the killer mechanism of recluse spider toxin
- IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- Etymological Investigation Disclosed: A Survey of \Dominating New Tongues\ Language Learning Application
- Vote in favor of your favored spot to peruse
- IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- Top 10 Smash hit Computer games of the Year
- Humpback whale freed by rescuers in Baltic Sea has become stranded again
- Dependable Savvy Locks to Update Your Home Security
- Becoming amazing at Arranging Pay Raises
